Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
C. Boutros, Ahmad A. Tarhini, Émilie Routier, et al.
Nature Reviews Clinical Oncology (2016) Vol. 13, Iss. 8, pp. 473-486
Closed Access | Times Cited: 947

Showing 1-25 of 947 citing articles:

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow, Robert Sidlow, Matthew D. Hellmann
New England Journal of Medicine (2018) Vol. 378, Iss. 2, pp. 158-168
Closed Access | Times Cited: 3689
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
John B.A.G. Haanen, Franck Carbonnel, Caroline Robert, et al.
Annals of Oncology (2017) Vol. 28, pp. iv119-iv142
Open Access | Times Cited: 2145
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
Igor Puzanov, Adi Diab, K. Abdallah, et al.
Journal for ImmunoTherapy of Cancer (2017) Vol. 5, Iss. 1
Open Access | Times Cited: 1713
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet, Robert Montal, Daniela Sia, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 10, pp. 599-616
Open Access | Times Cited: 1624
Inflammation and tumor progression: signaling pathways and targeted intervention
Huakan Zhao, Lei Wu, Guifang Yan, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1611
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 1265
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Lorenzo Galluzzi, Juliette Humeau, Aitziber Buqué, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 12, pp. 725-741
Closed Access | Times Cited: 1004
CTLA-4: a moving target in immunotherapy
Behzad Rowshanravan, Neil Halliday, David M. Sansom
Blood (2017) Vol. 131, Iss. 1, pp. 58-67
Open Access | Times Cited: 967
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba, et al.
JAMA Oncology (2017) Vol. 4, Iss. 3, pp. 374-374
Open Access | Times Cited: 873
EASL Clinical Practice Guidelines: Drug-induced liver injury
Raúl J. Andrade, Guruprasad P. Aithal, Einar S. Björnsson, et al.
Journal of Hepatology (2019) Vol. 70, Iss. 6, pp. 1222-1261
Closed Access | Times Cited: 853
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Marian L. Burr, Christina E. Sparbier, Yih-Chih Chan, et al.
Nature (2017) Vol. 549, Iss. 7670, pp. 101-105
Open Access | Times Cited: 781
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
John B.A.G. Haanen, Michel Obéid, Lavinia Spain, et al.
Annals of Oncology (2022) Vol. 33, Iss. 12, pp. 1217-1238
Open Access | Times Cited: 619
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Joerg Herrmann
Nature Reviews Cardiology (2020) Vol. 17, Iss. 8, pp. 474-502
Open Access | Times Cited: 517
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, et al.
Journal of the National Comprehensive Cancer Network (2019) Vol. 17, Iss. 3, pp. 255-289
Open Access | Times Cited: 516
In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
Chao Wang, Jinqiang Wang, Xudong Zhang, et al.
Science Translational Medicine (2018) Vol. 10, Iss. 429
Open Access | Times Cited: 514
Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Imran G. House, Peter Savas, Junyun Lai, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 2, pp. 487-504
Open Access | Times Cited: 509
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Leisha A. Emens, Paolo A. Ascierto, Phillip K. Darcy, et al.
European Journal of Cancer (2017) Vol. 81, pp. 116-129
Closed Access | Times Cited: 507
The hallmarks of successful anticancer immunotherapy
Lorenzo Galluzzi, Timothy A. Chan, Guido Kroemer, et al.
Science Translational Medicine (2018) Vol. 10, Iss. 459
Open Access | Times Cited: 491
Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 468
Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response
Oh Youn Kim, Hyun Taek Park, Nhung Thi Hong Dinh, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 465
In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
Chao Wang, Wujin Sun, Yanqi Ye, et al.
Nature Biomedical Engineering (2017) Vol. 1, Iss. 2
Closed Access | Times Cited: 464
TIGIT as an emerging immune checkpoint
Heidi Harjunpää, Camille Guillerey
Clinical & Experimental Immunology (2019) Vol. 200, Iss. 2, pp. 108-119
Open Access | Times Cited: 440
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, et al.
Journal of the National Comprehensive Cancer Network (2020) Vol. 18, Iss. 3, pp. 230-241
Open Access | Times Cited: 411
Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype
Degao Chen, Jing Xie, Roland Fiskesund, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 409
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
Noha Abdel‐Wahab, Mohsin Shah, María A. López-Olivo, et al.
Annals of Internal Medicine (2018) Vol. 168, Iss. 2, pp. 121-121
Closed Access | Times Cited: 405
Page 1 - Next Page

Scroll to top